Annual Total Liabilities
$130.15 M
+$8.87 M+7.31%
December 31, 2024
Summary
- As of March 13, 2025, TCRX annual total liabilities is $130.15 million, with the most recent change of +$8.87 million (+7.31%) on December 31, 2024.
- During the last 3 years, TCRX annual total liabilities has risen by +$102.82 million (+376.23%).
- TCRX annual total liabilities is now at all-time high.
Performance
TCRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$130.15 M
+$11.21 M+9.42%
December 31, 2024
Summary
- As of March 13, 2025, TCRX quarterly total liabilities is $130.15 million, with the most recent change of +$11.21 million (+9.42%) on December 31, 2024.
- Over the past year, TCRX quarterly total liabilities has increased by +$8.87 million (+7.31%).
- TCRX quarterly total liabilities is now -31.81% below its all-time high of $190.86 million, reached on March 31, 2021.
Performance
TCRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
TCRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +7.3% | +7.3% |
| 3 y3 years | +376.2% | +6.3% |
| 5 y5 years | +95.7% | +6.3% |
TCRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +376.2% | at high | +526.8% |
| 5 y | 5-year | at high | +376.2% | -31.8% | +526.8% |
| alltime | all time | at high | +376.2% | -31.8% | +526.8% |
TScan Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $130.15 M(+7.3%) | $130.15 M(+9.4%) |
| Sep 2024 | - | $118.94 M(-0.6%) |
| Jun 2024 | - | $119.65 M(+1.5%) |
| Mar 2024 | - | $117.86 M(-2.8%) |
| Dec 2023 | $121.28 M(+21.7%) | $121.28 M(-0.9%) |
| Sep 2023 | - | $122.42 M(-3.1%) |
| Jun 2023 | - | $126.32 M(+32.2%) |
| Mar 2023 | - | $95.56 M(-4.1%) |
| Dec 2022 | $99.66 M | $99.66 M(+104.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $48.80 M(+135.0%) |
| Jun 2022 | - | $20.76 M(-7.8%) |
| Mar 2022 | - | $22.51 M(-17.6%) |
| Dec 2021 | $27.33 M(-70.4%) | $27.33 M(-11.3%) |
| Sep 2021 | - | $30.82 M(-83.8%) |
| Jun 2021 | - | $190.04 M(-0.4%) |
| Mar 2021 | - | $190.86 M(+107.0%) |
| Dec 2020 | $92.20 M(+38.6%) | - |
| Dec 2020 | - | $92.20 M |
| Dec 2019 | $66.52 M | - |
FAQ
- What is TScan Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for TScan Therapeutics?
- What is TScan Therapeutics annual total liabilities year-on-year change?
- What is TScan Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for TScan Therapeutics?
- What is TScan Therapeutics quarterly total liabilities year-on-year change?
What is TScan Therapeutics annual total liabilities?
The current annual total liabilities of TCRX is $130.15 M
What is the all time high annual total liabilities for TScan Therapeutics?
TScan Therapeutics all-time high annual total liabilities is $130.15 M
What is TScan Therapeutics annual total liabilities year-on-year change?
Over the past year, TCRX annual total liabilities has changed by +$8.87 M (+7.31%)
What is TScan Therapeutics quarterly total liabilities?
The current quarterly total liabilities of TCRX is $130.15 M
What is the all time high quarterly total liabilities for TScan Therapeutics?
TScan Therapeutics all-time high quarterly total liabilities is $190.86 M
What is TScan Therapeutics quarterly total liabilities year-on-year change?
Over the past year, TCRX quarterly total liabilities has changed by +$8.87 M (+7.31%)